Wells Fargo & Company Renovo Rx, Inc. Transaction History

Wells Fargo & Company

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$1.02 - $1.98 $2 - $3	2 Added 2.99%	69 $0
Q4 2023 Feb 09, 2024	BUY	$0.6 - $2.29 $3 - $13	6 Added 9.84%	67 $0
Q3 2023 Nov 13, 2023	BUY	$1.3 - $2.3 $15 - $27	12 Added 24.49%	61 $0
Q2 2023 Aug 15, 2023	BUY	$1.85 - $3.21 $12 - $22	7 Added 16.67%	49 $0
Q1 2023 May 12, 2023	BUY	$2.51 - $5.25 $2 - $5	1 Added 2.44%	42 $0
Q4 2022 Feb 13, 2023	BUY	$1.65 - $2.35 $1 - $2	1 Added 2.5%	41 $0
Q3 2022 Nov 14, 2022	BUY	$1.84 - $2.79 $44 - $66	24 Added 150.0%	40 $0
Q2 2022 Aug 12, 2022	BUY	$1.52 - $2.99 $1 - $2	1 Added 6.67%	16 $0
Q1 2022 May 16, 2022	BUY	$2.87 - $4.9 $11 - $19	4 Added 36.36%	15 $0
Q4 2021 Feb 14, 2022	BUY	$4.72 - $8.5 $51 - $93	11 New	11 $0

2.87M

Ticker RNXT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 9,066,860
Market Cap $11.4M
Description
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, In...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.